Evidence map›Paper›PMID 37316921›Full record

ArticleJournal of ovarian research2023

Serum vascular endothelial growth factor associated with the progression of granulosa cell tumor: a report of two cases.

Kazuki Takasaki, Takayuki Ichinose, Yuko Miyagawa, Shiho Fukui, Kei Hashimoto, Haruka Nishida, Yuko Takahashi, Haruko Hiraike, Koji Saito, Yuko Sasajima and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kazuki TakasakiDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan.
Takayuki IchinoseDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan.
Yuko MiyagawaDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan.
Shiho FukuiDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan.
Kei HashimotoDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan.
Haruka NishidaDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan.
Yuko TakahashiDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan.
Haruko HiraikeDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan.
Koji SaitoDepartment of Pathology, Teikyo University School of Medicine, Tokyo, Japan.
Yuko SasajimaDepartment of Pathology, Teikyo University School of Medicine, Tokyo, Japan.
Kazunori NagasakaDepartment of Obstetrics and Gynecology, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi district, Tokyo, Japan. nagasakak@med.teikyo-u.ac.jp.
Teikyo University · JP

Funding

Grant-in-Aid for Scientific Research from the Ministry of Education 19K09834
6 · The paper itself

Abstract

backgroundGranulosa cell tumors (GCTs) account for approximately 2% of ovarian malignancies and are considered a rare type of ovarian cancer. GCTs are characterized by irregular genital bleeding after menopause due to female hormone production as well as late recurrence around 5-10 years after initial treatment. In this study, we investigated two cases of GCTs to find a biomarker that can be used to evaluate the treatment and predict recurrence. CASE PRESENTATION: Case 1 was a 56-year-old woman who presented to our hospital with abdominal pain and distention. An abdominal tumor was found, and GCTs were diagnosed. Serum vascular endothelial growth factor (VEGF) levels decreased after surgery. Case 2 involved a 51-year-old woman with refractory GCTs. Carboplatin-paclitaxel combination therapy and bevacizumab were administered after the tumor resection. After chemotherapy, a decline in VEGF levels was observed, but serum VEGF levels increased again with disease progression.

conclusionsVEGF expression may be of clinical importance in GCTs as a clinical biomarker for disease progression, which may be used to determine the efficacy of bevacizumab against GCTs.

Indexed as

Granulosa Cell TumorOvarian NeoplasmsBevacizumabDisease ProgressionFemaleHumansMiddle AgedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsBevacizumabVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsChemotherapyGranulosa cell tumorVascular endothelial growth factor

Identifiers

PMID37316921
PMCPMC10265796
OpenAlexW4380686115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.